LAVA Therapeutics's total assets for Q2 2025 were $60.55M, a decrease of -14.91% from the previous quarter. LVTX total liabilities were $40.61M for the fiscal quarter, a -10.49% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.